Ur Rehman Muhammad Fazal, Imran Zaidi Ali, Ul Haq Tanveer, Rafique Shoaib, Ali Farman
Urology, Bakhtawar Amin Medical and Dental College, Multan, PAK.
Urology, Multan Institute of Kidney Diseases, Multan, PAK.
Cureus. 2020 Sep 29;12(9):e10725. doi: 10.7759/cureus.10725.
Objective The goal of this study was to compare the efficacy of tramadol and paroxetine in the treatment of primary premature ejaculation (PE). Study design This study was a randomized controlled trial performed in the outpatient department of Nishtar Hospital, Multan, from January 2017 to January 2018. Methodology One hundred six patients were diagnosed with PE and included in the study. The patients were categorized into two groups receiving either tramadol or paroxetine through a lottery randomization method. The main variables were baseline PE, baseline satisfaction after intercourse, baseline intravaginal ejaculatory latency time (IELT), ejaculation control, difficulty in ejaculation, and after-treatment satisfaction with sexual intercourse and IELT. We used IBM SPSS Statistics for Windows, Version 23.0 (Armonk, NY: IBM Corp.) for data analysis, and p≤0.05 was considered statistically significant. Results Ejaculation control, difficulty in ejaculation, and distress due to ejaculation in patients in the tramadol group was noted as 24.5%, 7.5%, and 7.5%, respectively. Ejaculation control, difficulty in ejaculation, and distress due to ejaculation in the paroxetine group was noted as 49.1%, 17%, and 24.5%, respectively. The differences were statistically significant within the groups at baseline and after treatment of PE (p<0.001). Conclusion Tramadol is an effective and useful drug as compared to paroxetine for the treatment of PE. Tramadol can be used as an alternative to other medications for the treatment of lifelong PE.
目的 本研究的目的是比较曲马多和帕罗西汀治疗原发性早泄(PE)的疗效。
研究设计 本研究是一项随机对照试验,于2017年1月至2018年1月在木尔坦尼什塔尔医院门诊部进行。
方法 106例患者被诊断为早泄并纳入研究。通过抽签随机化方法将患者分为两组,分别接受曲马多或帕罗西汀治疗。主要变量包括基线早泄情况、性交后基线满意度、基线阴道内射精潜伏期(IELT)、射精控制、射精困难以及治疗后性交满意度和IELT。我们使用IBM SPSS Statistics for Windows,版本23.0(纽约州阿蒙克:IBM公司)进行数据分析,p≤0.05被认为具有统计学意义。
结果 曲马多组患者的射精控制、射精困难和射精困扰分别为24.5%、7.5%和7.5%。帕罗西汀组的射精控制、射精困难和射精困扰分别为49.1%、17%和24.5%。在基线和早泄治疗后,组内差异具有统计学意义(p<0.001)。
结论 与帕罗西汀相比曲马多是一种治疗早泄的有效且有用的药物。曲马多可作为治疗终身性早泄的其他药物的替代品。